Oncoustics AI
Ahmed E. has a strong background in imaging science, with a focus on quantitative imaging in the context of oncology. Ahmed has worked at Stanford University as an Instructor, where they specialized in quantitative ultrasound and validation techniques for tissue characterization. Ahmed also served as a Research Fellow at Stanford University.
Ahmed is a Co-Founder of Oncoustics Inc., a company aimed at accelerating the commercialization of intellectual property produced at Sunnybrook Hospital in quantitative ultrasound imaging. In this role, Ahmed was responsible for fundraising, negotiating licensing of intellectual property, and initial product development.
Prior to their work at Stanford and Oncoustics, Ahmed was a Postdoctoral Research Fellow at Sunnybrook Research Institute, where they extended novel ultrasound methods for assessing biophysical vascular targeting strategies in cancer therapy. Ahmed also developed ultrasound as a tool in radiation oncology imaging and explored ultrasound-based therapeutic approaches to augment radiation therapy.
Ahmed holds a Ph.D. from Sunnybrook Health Sciences Centre / University of Toronto, where they focused on their research in the field of imaging science.
Ahmed E. completed their education in a sequential manner as follows:
From 2015 to 2017, Ahmed pursued postdoctoral studies at Stanford University, specializing in Imaging Sciences/Radiology.
Between 2008 and 2013, they attended the University of Toronto, where they obtained a Ph.D. in Medical Biophysics, focusing on Imaging and Radiation Oncology Research.
Starting in 2006 and concluding in 2008, Ahmed pursued a Master of Science (M.Sc.) degree in Biomedical Physics at Ryerson University.
Ahmed's education journey began at Ryerson University from 2001 to 2005, where they completed a bachelor's degree in Electrical and Computer Engineering.
Moreover, aside from their formal education, Ahmed obtained certification from the Creative Destruction Lab at the Rotman School of Management, University of Toronto. However, the specific month and year of obtaining this certification information are not provided.
This person is not in any teams
This person is not in any offices
Oncoustics AI
Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers.